Αρχική World News Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage... World News Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma Από Ogkologos - 2 Φεβρουαρίου, 2026 510 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Survivor Story: Erin 4 Ιουνίου, 2021 Junk food marketing restrictions: so near and yet so far 15 Δεκεμβρίου, 2022 FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... 15 Ιουλίου, 2024 Feeding the Gut 14 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS How to Provide Support as a Long-Distance Cancer Caregiver Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of... Primary Tumour Resection Does Not Prolong OS in Patients with Treatment-Naïve... Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with...
